Stephen Saklad, PharmD, BCPP
Director, Psychiatric Pharmacy Program and Clinical Professor
The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, Texas; and UT Health San Antonio, Joe R. & Teresa Lozano Long School of Medicine, Pharmacotherapy Education and Research Center, San Antonio, Texas
The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division
San Antonio, Texas
There are many drug-drug interactions that can become clinically significant problems if not well understood and anticipated. Not all drug-drug interactions are harmful, but when poorly understood can lead to disastrous results. This session will discuss the most common problems observed due to psychiatric drugs, including include additive or synergistic pharmacodynamic effects; increased metabolic activity causing decreased or loss of efficacy due to increased elimination; decreased metabolic activity causing decreased or loss of efficacy due to decreased conversion to active metabolite; and changes in sodium cause increases or decreases in lithium efficacy and toxicity.